57381-36-9

Basic information

• Product Name: RARECHEM AL BF 1329
• Synonyms: RARECHEM AL BF 1329;Methyl 5-chloro-2-fluorobenzoate
• CAS NO: 57381-36-9
• Molecular Formula: C₈H₆ClFO₂
• Molecular Weight: 188.58
• Mol File: 57381-36-9.mol

Chemical Properties

• Boiling Point: 245.0±25.0 °C(Predicted)
• Appearance: /
• Density: 1.314±0.06 g/cm3(Predicted)
• CAS DataBase Reference: RARECHEM AL BF 1329(CAS DataBase Reference)
• NIST Chemistry Reference: RARECHEM AL BF 1329(57381-36-9)
• EPA Substance Registry System: RARECHEM AL BF 1329(57381-36-9)

Safety Data

• Hazardous Substances Data: 57381-36-9(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 394-29-6 5-chloro-2-fluoro-benzoyl chloride 
• 394-30-9 5-chloro-2-fluorobenzoic acid 
• 144-55-8 sodium hydrogencarbonate 
• 79-37-8 oxalyl dichloride 

Downstream Products

• 657424-44-7 5-chloro-2-fluoro-benzoic acid hydrazide 
• 1153285-33-6 methyl 5-chloro-2-fluoro-3-nitrobenzoate 
• 1269421-13-7 3-amino-5-chloro-2-fluorobenzoic acid methyl ester 
• 1269421-14-8 5-chloro-2-fluoro-3-(propylsulfonamido)benzoic acid 
• 1192347-43-5 methyl 5-chloro-2-(methylsulfonyl)benzoate 
• 1192347-44-6 [5-chloro-2-(methylsulfonyl)phenyl]methanol 
• 1192347-45-7 2-(bromomethyl)-4-chloro-1-(methylsulfonyl)benzene 
• 720689-28-1 5-chloro-2-(methylsulfonyl)benzoic acid 
• 861306-45-8 Methyl 5-chloro-2-(methylsulfanyl)benzoate 

Relevant articles and documents

CRYSTALLINE ALK5 INHIBITORS AND USES THEREOF

The present disclosure provides crystalline forms of activin receptor-like kinase 5 (ALK5) inhibitors. Also disclosed are pharmaceutical compositions comprising the crystalline forms, methods of using the crystalline forms to modulate the activity of ALK5 and methods of treating disorders mediated by ALK5 using the crystalline forms.

ALK5 INHIBITORS

The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

Preparation method of halogenated benzothiazepine compound as well as product prepared by preparation method and application of halogenated benzothiazepine compound

The invention discloses a preparation method of a halogenated benzothiazepine compound as well as a product prepared by the preparation method and an application of the halogenated benzothiazepine compound, and relates to the technical field of chemical s

Structure determination, synthesis, and biological evaluation of a metabolite of the selective α1Dadrenoceptor antagonist TAK-259

5-Chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide hydrochloride (TAK-259) is a novel, selective, and orally active α1Dadrenoceptor antagonist with anti-urinary frequency effect. A metabolite (2) of TAK-259 was identified from monkey urine samples. To elucidate the structure of 2, extraction and purification of the metabolite from TAK-259-treated monkey urine was conducted. Structural analysis of the purified compounds using NMR indicated the compound to be 2-amino-5-chloro-1-[5-chloro-2-(methylsulfonyl)benzyl]-4-oxo-1,4-dihydropyridine-3-carboxamide (2a). An authentic sample of compound 2a was synthesized via regioselective alkylation of 4-methoxypyridin-2-amine. The biological activity of metabolite 2a was also evaluated, and the compound found not to possess affinity toward any known α1adrenoceptor subtype.

NEW COMPOUNDS

The present invention relates to new compounds of formula I, (I) a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

NEW COMPOUNDS

The present invention relates to new compounds of formula (I), wherein P, Q, X1, X2, X3, X4, R, R1, R2, R3, R4, R5, R6, R7, m, n, o, p and q are defined as in any one of claims 1 to 12, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

Aryl triazines as LPAAT-SS inhibitors and uses thereof

The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor cells.